Galapagos NV: Galapagos to present new data from long-term extension study of filgotinib in ulcerative colitis at annual ECCO congress 2023

Six presentations demonstrate Galapagos' commitment to the inflammatory bowel disease (IBD) communityNew analyses from Phase 3 SELECTION and SELECTION long-term extension (LTE) studies of Jyseleca® (filgotinib

Related Keywords

United Kingdom ,Mechelen ,Region Flamande ,Belgium ,Japan ,Canada ,Northern Ireland ,Craigavon ,London ,City Of ,Japanese ,Great Britain ,Daniele Dambrosio ,Dennis Riedl ,Ailsa Hart ,Roberta Loveikyte ,Kristina Harris ,Pieter Jan Stiers ,Katrien Van Beneden ,Van Gijsel ,Briang Feagan ,Takayuki Matsumoto ,Andreas Sturm ,Christine Rudolph ,Hannah Knight ,Eva Santermans ,Brian Feagan ,Stefan Schreiber ,Fatima Dawod ,Tadakazu Hisamatsu ,Karine Muller ,Roger Rolph ,Marieke Vermeersch ,Edouard Louis ,Sandra Cauwenberghs ,Taku Kobayashi ,Johan Burisch ,Alessandra Oortwijn ,Paul Van Hoek ,Alessandro Armuzzi ,Sarah Weatherby ,Laurent Peyrin Biroulet ,Corinne Jamoul ,Katsuyoshi Matsuoka ,Gerhard Rogler ,Elisa Chenailler ,Bart Eskens ,Colitis Organization ,Exchange Commission ,Japanese Ministry Of Health ,Twitter ,European Union ,European Medicines Agency ,Gilead Sciences Inc ,European Crohn ,Mayo Clinic Score ,Danieled Ambrosio ,Therapeutic Area Head ,Inflammatory Bowel Disease ,Western University ,Ulcerative Colitis ,Margaux Faes ,Angela De Haas ,Poster Exhibition ,Meulen De Jong ,Rachael Meadows ,European Summary ,Product Characteristics ,Great Britain Summary ,Northern Ireland Summary ,Japanese Ministry ,Gilead Sciences ,Inflammatory Bowel Disease Questionnaire ,Galapagos ,Present ,Data ,Rom ,Song ,Term ,Extension ,Study ,Filgotinib ,Ulcerative ,Colitis ,Nnual ,Cco ,Congress ,023 ,